GLP-1 medications have changed the conversation around weight management. For employers, the question is no longer simply whether these medications work or whether to cover them. It’s how to make a coverage decision that fits the needs of their population and supports better outcomes over time.
That means looking beyond the pharmacy line item.
Before making a GLP-1 coverage decision, employers should understand who they’re trying to reach, what role medication should play in their broader weight-management strategy, how they’ll measure value, and what happens after an employee starts treatment.
Here are 10 questions to help guide the conversation.
Understand your population
1. Who are we trying to reach, and who might we be missing?
Start with your population, not the medication.
How many employees may be eligible for GLP-1s? How many are already using them? And what about people with emerging weight-related risk who aren’t yet taking medication or may not yet have a diagnosis?
A coverage strategy designed only around current GLP-1 utilization can miss people earlier in the weight-health journey who may benefit from support before risk becomes a more significant health or cost concern.
The question: Do we understand the full population we’re trying to serve, not just the people we can already see in our claims data?
2. What problem are we actually trying to solve?
GLP-1 coverage can serve different goals, and those goals should be clear before decisions are made.
Are you primarily trying to manage rising pharmacy costs? Improve weight-related health outcomes? Support employees who are already taking medication? Reduce downstream healthcare costs? Reach people earlier?
There may be more than one answer. But defining the objectives upfront makes it easier to determine what kind of coverage and support your population needs, and how you’ll measure success.
The question: Have we defined what success looks like, or are we assuming it’s the same thing for everyone?
3. How will we identify the right people for the right level of care?
Knowing how many people are eligible for GLP-1s is only part of the picture. Employers also need to understand how they’ll identify people who may benefit from different levels of support.
That may require looking across multiple sources of population data and understanding what signals indicate emerging risk, current need, or an opportunity for earlier intervention.
The question: Do we have the data and analytics needed to connect people with the level of care that fits their needs?
Design the right strategy
4. What role should GLP-1s play in our broader weight-management strategy?
Medication doesn’t have to be an either/or decision.
A comprehensive weight-management strategy can consider how medication works alongside behavior change, nutrition, clinical care, and other benefits. The goal isn’t to steer every employee toward or away from one intervention. It’s to make sure people can access appropriate support based on their individual needs.
The question: Where do GLP-1s fit within the larger weight-management ecosystem we’re building?
5. What happens after someone starts a GLP-1?
Coverage is a starting point, not the entire care journey.
Employees will need support with nutrition, behavior change, adherence, side effects, lifestyle changes, and maintaining progress over time. Employers should understand what happens beyond the prescription, and whether their strategy is designed to support people throughout treatment.
The question: What support surrounds the medication once an employee starts treatment?
6. How will employees access care, and how much choice will they have?
There are different ways to structure GLP-1 access. Employers should consider whether medication is available independently, integrated with a weight-management program, or connected to different levels of clinical and behavioral support. Employee needs and preferences won’t be identical, either.
The question: Does our approach give employees an appropriate level of access, support, and choice?
Define value
7. Are we looking at total cost of care, or just the pharmacy line item?
GLP-1 spend can be significant. But evaluating the strategy solely through the pharmacy line item can miss the broader picture.
Weight-related health conditions can affect healthcare utilization and costs across the benefit ecosystem, not just pharmacy spend. Employers should consider the potential impact of earlier intervention, improved health outcomes, and reduced downstream risk alongside the direct cost of medication.
The question: Are we evaluating GLP-1 spend as part of the total cost of care, or in isolation?
8. How will we measure ROI?
If prevention and earlier intervention are part of the strategy, employers need to define what success looks like before the savings show up.
That means identifying the outcomes that matter, establishing a timeframe for measurement, and understanding which costs and savings are included in the ROI calculation. Employers should also expect their vendors to bring real population-level data to the conversation, not just a headline number.
The question: Can our partner show us what is changing in our population, and how those changes translate into value?
9. How will we know whether the strategy is actually working?
Enrollment and prescriptions are easy to count. They’re not necessarily enough to demonstrate impact.
Employers should consider measures such as engagement, retention, health outcomes, medication adherence, and other population-level indicators that align with their goals.
The most useful metrics will depend on the strategy and population, but the principle is the same: measure what matters, not just what’s easiest to count.
The question: Do we have a clear way to distinguish utilization from meaningful outcomes?
Plan for what’s next
10. Can our strategy adapt as the landscape changes?
The GLP-1 landscape isn’t standing still. New medications, evolving evidence, changing costs, and shifting employee needs will continue to shape weight-management strategy.
A coverage decision made today shouldn’t lock an employer into a strategy that can’t evolve tomorrow.
The question: Can our approach adapt as the science, treatment landscape, and needs of our population change?
The GLP-1 decision is bigger than the prescription
A GLP-1 coverage decision is ultimately a decision about how an employer wants to approach weight management as a whole, not just who gets access to medication, but who needs support, when, what kind, and how to measure whether it’s working.
Explore Wondr Health for your weight benefit strategy
Wondr Health brings together behavior change, personalized clinical care, and tailored medication management to help employers support people across the weight-health continuum.
The goal isn’t simply to cover GLP-1s. It’s to build a weight-management strategy that improves the health of your people and your bottom line.
Ready to take a closer look at what a more comprehensive weight and GLP-1 strategy could look like for your organization? Contact us today.
